January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
5 Articles in Immunotherapy suggested by Wafik El-Deiry
Jan 10, 2025, 18:33

5 Articles in Immunotherapy suggested by Wafik El-Deiry

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget.

Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.

Wafik El-Deiry

Wafik El-Deiry shared a few must-reads paper on X:

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data

Authors: Seong-Keun Yoo et al.

5 Articles in Immunotherapy suggested by Wafik El-Deiry

Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer

Authors: Laura Jinxuan Wu et al.

5 Articles in Immunotherapy suggested by Wafik El-Deiry

Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding

Authors: Jiancheng Gao et al.

5 Articles in Immunotherapy suggested by Wafik El-Deiry

Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials

Authors: Akshay J. Patel et al.

5 Articles in Immunotherapy suggested by Wafik El-Deiry

Cancer immune evasion, immunoediting and intratumour heterogeneity

Authors: Malte Roerden et al.

5 Articles in Immunotherapy suggested by Wafik El-Deiry